Company intelligence / Profile preview

Kentegra Biotechnology

Ownership: Private
Development stage: Commercial

Overview

Kentegra Biotechnology produces premium-grade Pale Refined Extract from the pyrethrum flower, used as a 100% natural active ingredient in manufacturing insecticides and pesticides. The company partners with over 20,000 Kenyan smallholder farmers to source raw materials and has developed new pyrethrum varieties registered in Kenya. Their operations support sustainable farming practices and provide significant socio-economic benefits to local communities. The extract offers an environmentally friendly alternative to synthetic pesticides.

Therapeutic areas: Other
Modalities: Natural product extract (Pale Refined Extract from pyrethrum flower)
Industry: Non-Drug Biotech

Drug pipeline

1 asset

pyrethrin

Commercial

Indications: Natural pesticide

Partnerships

Finnfund (investor/financing partner)Talanton LLC (investor)

Beyond the preview

Go deeper on Kentegra Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kentegra Biotechnology.

Explore the full profile